Latest Breaking News On - Medicine mcmaster university division of infectious disease - Page 1 : comparemela.com

TORONTO, Sept. 20, 2022 /CNW/ - Takeda Canada Inc. is pleased to announce that Health Canada has authorized LIVTENCITY™ for the treatment of adults with post-transplant cytomegalovirus . | September 20, 2022

United statesShannon lowe emeryEl chaerClin virolShariq haiderTakeda canada incTakeda pharmaceutical company limitedResearch lead transplant malignant id juravinski hospitalWorld health organizationCancer centerMedicine mcmaster university division of infectious diseaseSpringer international publishingHealth canadaTakeda canadaMcmaster university divisionInfectious disease